Search Results - "GRØNBERG, Bjorn H"

Are We Finally Ready to Implement Twice-Daily Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer? by Grønberg, Bjørn H.

Get full text

Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer by Stene, Guro B, Helbostad, Jorunn L, Amundsen, Tore, Sørhaug, Sveinung, Hjelde, Harald, Kaasa, Stein, Grønberg, Bjørn H

“…Sarcopenia is a defining feature of cancer cachexia associated with physical decline, poor quality of life and poor prognosis. Thus, maintaining muscle mass is…”
Get more information

Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer by GRØNBERG, Bjorn H, BREMNES, Roy M, WAMMER, Finn, AASEBØ, Ulf, SUNDSTRØM, Stein, FLØTTEN, Øystein, AMUNDSEN, Tore, BRUNSVIG, Paal Fr, HJELDE, Harald H, KAASA, Stein, VON PLESSEN, Christian, STORNES, Froydis, TOLLALI, Terje

“…PURPOSE To compare pemetrexed/carboplatin with a standard regimen as first-line therapy in advanced non-small-cell lung cancer NSCLC. PATIENTS AND METHODS…”
Get full text

Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling by Pettersen, Kristine, Andersen, Sonja, Degen, Simone, Tadini, Valentina, Grosjean, Joël, Hatakeyama, Shinji, Tesfahun, Almaz N., Moestue, Siver, Kim, Jana, Nonstad, Unni, Romundstad, Pål R., Skorpen, Frank, Sørhaug, Sveinung, Amundsen, Tore, Grønberg, Bjørn H., Strasser, Florian, Stephens, Nathan, Hoem, Dag, Molven, Anders, Kaasa, Stein, Fearon, Kenneth, Jacobi, Carsten, Bjørkøy, Geir

“…The majority of cancer patients with advanced disease experience weight loss, including loss of lean body mass. Severe weight loss is characteristic for cancer…”
Get full text

Associations Between Time to Treatment Start and Survival in Patients With Lung Cancer by Stokstad, Trine, Sørhaug, Sveinung, Amundsen, Tore, Grønberg, Bjørn H

“…Time-to-treatment is defined as a quality indicator for cancer care but is not well documented. We investigated whether meeting Norwegian timeframes of 35/42…”
Get full text

Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer by Sjøblom, Bjørg, Grønberg, Bjørn H, Wentzel-Larsen, Tore, Baracos, Vickie E, Hjermstad, Marianne J, Aass, Nina, Bremnes, Roy M, Fløtten, Øystein, Bye, Asta, Jordhøy, Marit

“…Summary Background & aims Recent research indicates that severe muscular depletion (sarcopenia) is frequent in cancer patients and linked to cachexia and poor…”
Get full text

Muscle mass and association to quality of life in non‐small cell lung cancer patients by Bye, Asta, Sjøblom, Bjørg, Wentzel‐Larsen, Tore, Grønberg, Bjørn H., Baracos, Vickie E., Hjermstad, Marianne J., Aass, Nina, Bremnes, Roy M., Fløtten, Øystein, Jordhøy, Marit

“…Background Cancer wasting is characterized by muscle loss and may contribute to fatigue and poor quality of life (QoL). Our aim was to investigate associations…”
Get full text

Fragmentation assessment of FFPE DNA helps in evaluating NGS library complexity and interpretation of NGS results by Ottestad, Anine Larsen, Emdal, Elisabeth F., Grønberg, Bjørn H., Halvorsen, Tarje O., Dai, Hong Yan

“…Formalin-fixed paraffin-embedded (FFPE) tissue remains the most common source for DNA extraction from human tissue both in research and routine clinical…”
Get full text

Reasons for prolonged time for diagnostic workup for stage I-II lung cancer and estimated effect of applying an optimized pathway for diagnostic procedures by Stokstad, Trine, Sørhaug, Sveinung, Amundsen, Tore, Grønberg, Bjørn H

“…Minimizing the time until start of cancer treatment is a political goal. In Norway, the target time for lung cancer is 42 days. The aim of this study was to…”
Get full text

Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer by Sjøblom, Bjørg, Grønberg, Bjørn H, Benth, Jūratė Šaltytė, Baracos, Vickie E, Fløtten, Øystein, Hjermstad, Marianne J, Aass, Nina, Jordhøy, Marit

“…Highlights • Body surface area (BSA) does not reflect differences in body compostion. • Dose estimation by BSA gave large variations in dose per kg lean body…”
Get full text

A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer by Grønberg, Bjørn H., Sjøblom, Bjørg, Wentzel-Larsen, Tore, Baracos, Vickie E., Hjermstad, Marianne J., Aass, Nina, Bremnes, Roy M., Fløtten, Øystein, Bye, Asta, Jordhøy, Marit

“…Background: Muscle mass and density assessed from CT-images at the L3 level are prognostic for survival and predict toxicity in cancer patients. However, L3 is…”
Get full text

Medical complexity and time to lung cancer treatment - a three-year retrospective chart review by Stokstad, Trine, Sørhaug, Sveinung, Amundsen, Tore, Grønberg, Bjørn H

“…The time from a referral for suspected lung cancer is received at a hospital until treatment start has been defined as a quality indicator. Current Norwegian…”
Get full text

Characterization of patients receiving palliative chemo- and radiotherapy during end of life at a regional cancer center in Norway by Anshushaug, Malin, Gynnild, Mari Aas, Kaasa, Stein, Kvikstad, Anne, Grønberg, Bjørn H

“…Many cancer patients receive chemotherapy and radiotherapy their last 30 days [end of life (EOL)]. The benefit is questionable and side effects are common. The…”
Get more information

Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer by Lund-Iversen, Marius, Scott, Helge, Strøm, Erik H, Theiss, Noah, Brustugun, Odd Terje, Grønberg, Bjørn H

“…The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated…”
Get full text

Case Report: Limbic encephalitis following treatment with durvalumab for small-cell lung cancer by Moss, Thomas T., Stavem, Knut, Aandahl, Astrid, Gløersen, Anne S., Grønberg, Bjørn H., Neumann, Kirill, Vedeler, Christian A., Lundqvist, Christofer

“…Background Durvalumab is an immune checkpoint Inhibitor (ICIs) that is used in the treatment of malignant tumors, such as lung cancer and melanoma. ICIs are…”
Get full text

Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNA by Dunwell, Thomas L., Dailey, Simon C., Ottestad, Anine L., Yu, Jihang, Becker, Philipp W., Scaife, Sarah, Richman, Susan D., Wood, Henry M., Slaney, Hayley, Bottomley, Daniel, Yang, Xiangsheng, Xiao, Hui, Wahl, Sissel G. F., Grønberg, Bjørn H., Dai, Hongyan, Fu, Guoliang

“…Liquid biopsy testing utilising Next Generation Sequencing (NGS) is rapidly moving towards clinical adoption for personalised oncology. However, before NGS can…”
Get full text

Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy by Grønberg, Bjørn H, Lund-Iversen, Marius, Strøm, Erik H, Brustugun, Odd Terje, Scott, Helge

“…Pemetrexed is effective in the treatment of non-small-cell lung cancer, mainly in nonsquamous cell carcinomas. Inhibition of thymidylate synthase (TS) is…”
Get more information

Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer by Grønberg, Bjørn H, Halvorsen, Tarje O, Fløtten, Øystein, Brustugun, Odd T, Brunsvig, Paal F, Aasebø, Ulf, Bremnes, Roy M, Tollåli, Terje, Hornslien, Kjersti, Aksnessæther, Bjørg Y, Liaaen, Erik D, Sundstrøm, Stein

“…Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well…”
Get more information

Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non–Small-Cell Lung Cancer by Sjøblom, Bjørg, Benth, Jūratė Šaltytė, Grønberg, Bjørn H., Baracos, Vickie E., Sawyer, Michael B., Fløtten, Øystein, Hjermstad, Marianne J., Aass, Nina, Jordhøy, Marit

“…Variations in lean body mass (LBM) are proposed to contribute to interindividual differences in toxicity from cancer drugs. In advanced non–small-cell lung…”
Get full text

Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy by Grønberg, Bjørn H, Sundstrøm, Stein, Kaasa, Stein, Bremnes, Roy M, Fløtten, Øystein, Amundsen, Tore, Hjelde, Harald H, Plessen, Christian von, Jordhøy, Marit

“…Abstract Aim of the study To investigate whether patients with severe comorbidity receiving platinum-based chemotherapy for advanced non-small-cell lung cancer…”
Get full text